Related Experiment Video
Updated: Dec 27, 2025
08:25
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.9K
Expression of ABCA7 in Alzheimer's disease
1Neurodegenerative Brain Diseases Group, VIB-Center for Molecular Neurology, University of Antwerp-CDE, Universiteitsplein 1, 2610, Antwerp, Belgium. kristel.sleegers@uantwerpen.vib.be.
Acta Neuropathologica
|March 1, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:22Alzheimer's Disease: Treatment
699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699